Romyelocel-L is under clinical development by Cellerant Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Romyelocel-L’s likelihood of approval (LoA) and phase transition for Neutropenia took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Romyelocel-L Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Romyelocel-L overview

Romyelocel L (CLT-008) is under development for the treatment of chemotherapy-induced neutropenia in patients with acute myeloid leukemia, and for the treatment of neutropenia in patients receiving umbilical cord blood transplantation and in patients with acute radiation syndrome. It is also under development for the treatment of organ transplant. The drug candidate is administered through intravenous route. CLT-008 is derived from adult blood-forming stem cells. The drug candidate is cryopreserved, cell-based therapy that contains human myeloid progenitor cells derived from adult stem cells. It is based on hematopoietic stem cell (HSC) purification technology.

Cellerant Therapeutics overview

Cellerant Therapeutics (Cellerant) is a clinical-stage biotechnology company that develops novel immunotherapies for oncology and blood-related disorders. The company’s pipeline products include myeloid progenitor cell, megakaryoid progenitor cell, myeloid-derived suppressor cells and therapeutic antibodies. It develops various cell therapy products and antibodies against malignant cells using its hematopoietic stem cell biology technology. Cellerant also develops processes for autologous and allogeneic cell therapy manufacturing using its cell therapy process development technology. The company offers cancer stem cell antibody discovery program on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome. Cellerant is headquartered in San Carlos, California, the US.

Quick View Romyelocel-L LOA Data

Report Segments
  • Innovator
Drug Name
  • Romyelocel-L
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
  • Immunology
  • Toxicology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.